Barclays PLC Gracell Biotechnologies Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$2.43 - $10.04 $731,437 - $3.02 Million	-301,003 Reduced 96.62%	10,517 $106,000
Q3 2023 Nov 07, 2023	BUY	$2.83 - $4.9 $851,838 - $1.47 Million	301,003 Added 2862.06%	311,520 $898,000
Q2 2023 Aug 03, 2023	SELL	$1.45 - $6.07 $278,121 - $1.16 Million	-191,808 Reduced 94.8%	10,517 $40,000
Q1 2023 May 04, 2023	BUY	$1.8 - $2.5 $209,188 - $290,540	116,216 Added 134.96%	202,325 $376,000
Q4 2022 Feb 13, 2023	BUY	$2.08 - $3.96 $98,548 - $187,620	47,379 Added 122.33%	86,109 $198,000

Q3 2022 Nov 03, 2022	SELL	$2.08 - $5.15 $3,536 - $8,755	-1,700 Reduced 4.2%	38,730 $125,000
Q2 2022 Aug 12, 2022	BUY	$1.95 - $5.5 $78,838 - $222,365	40,430 New	40,430 $222,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.